Gruss 305Albert Einstein Radiation Biology & Molecular-Immune Therapeutics is a full-service Contract Research Organization (CRO) dedicated to advancing preclinical and translational science. Our integrated platform combines radiation sciences, molecular and immune assays, preclinical tumor modeling, ultrasound therapeutics, and advanced bioinformatics. We offer specialized services including ligand–receptor interaction studies, recombinant protein production, hematopoietic and gastrointestinal functional assays, and in vivo models for drug screening, pharmacokinetics, and immunization. With state-of-the-art imaging, rigorous quality control, and a proven track record of peer-reviewed research, we deliver customized solutions that accelerate therapeutic discovery and development for biotech, pharma, and academic partners. Description of Services: Albert Einstein Radiation Biology & Molecular-Immune Therapeutics offers a comprehensive suite of preclinical and translational research services designed to support pharmaceutical, biotechnology, and academic partners in drug discovery and development. Our unique strength lies in integrating radiation biology, immunology, imaging, and molecular therapeutics into cohesive platforms for testing therapeutic efficacy, safety, and mechanism of action. Our Radiation Biology Services include precision small-animal irradiation using CT-guided platforms, cabinet irradiators, and well-established acute radiation syndrome models (hematopoietic, gastrointestinal, and lung). These systems are supported by full dosimetry and quality assurance infrastructure to ensure reproducibility and translational relevance. Our Immunology and Molecular Therapeutics Services encompass immune cell phenotyping, cytotoxic T-cell assays, ELISpot, cytokine profiling, immunogenic cell death assays, and ligand–receptor interaction studies. We provide high-throughput cell-microarray assays, receptor-binding assays, phosphorylation antibody arrays, and cytokine Luminex panels to validate targets and assess immune modulation. In addition, we offer recombinant protein production in bacterial and mammalian systems, with quality control through SEC, HPLC, mass spectrometry, and endotoxin testing. Our Imaging Services support functional and anatomical analyses using PET, SPECT, CT, and live-cell imaging systems such as Cytation 5. These platforms allow visualization of drug activity, biodistribution, tumor–immune interactions, and therapeutic responses in real time. Ultrastructural characterization using electron microscopy and specialized in vivo functional assays for gastrointestinal absorption and barrier integrity further strengthen our imaging-based assessments. Our Preclinical Models include a wide spectrum of orthotopic, metastatic, and genetically engineered mouse models for breast, lung, pancreatic, prostate, melanoma, and osteosarcoma research. These are complemented by organoid and enteroid systems for both normal tissue and tumor biology, enabling high-throughput efficacy and toxicity screening. Our Bioinformatics Solutions provide advanced analysis of single-cell sequencing, CITE-seq, spatial transcriptomics, bulk RNA-seq, and proteomics datasets. Supported by high-performance computing, our team delivers actionable insights through integrative analyses, pathway discovery, and data visualization. Together, these services create a full-service CRO platform that enables comprehensive evaluation of novel agents—from molecular design and target validation to in vivo efficacy, toxicity, and mechanistic studies—ensuring rigorous and translationally relevant outcomes for our partners.

1300 Morris Park Avenue Bronx, NY 10461Albert Einstein Radiation Biology & Molecular-Immune Therapeutics is a full-service Contract Research Organization (CRO) dedicated to advancing preclinical and translational science. Our integrated platform combines radiation sciences, molecular and immune assays, preclinical tumor modeling, ultrasound therapeutics, and advanced bioinformatics. We offer specialized services including ligand–receptor interaction studies, recombinant protein production, hematopoietic and gastrointestinal functional assays, and in vivo models for drug screening, pharmacokinetics, and immunization. With state-of-the-art imaging, rigorous quality control, and a proven track record of peer-reviewed research, we deliver customized solutions that accelerate therapeutic discovery and development for biotech, pharma, and academic partners. Description of Services: Albert Einstein Radiation Biology & Molecular-Immune Therapeutics offers a comprehensive suite of preclinical and translational research services designed to support pharmaceutical, biotechnology, and academic partners in drug discovery and development. Our unique strength lies in integrating radiation biology, immunology, imaging, and molecular therapeutics into cohesive platforms for testing therapeutic efficacy, safety, and mechanism of action. Our Radiation Biology Services include precision small-animal irradiation using CT-guided platforms, cabinet irradiators, and well-established acute radiation syndrome models (hematopoietic, gastrointestinal, and lung). These systems are supported by full dosimetry and quality assurance infrastructure to ensure reproducibility and translational relevance. Our Immunology and Molecular Therapeutics Services encompass immune cell phenotyping, cytotoxic T-cell assays, ELISpot, cytokine profiling, immunogenic cell death assays, and ligand–receptor interaction studies. We provide high-throughput cell-microarray assays, receptor-binding assays, phosphorylation antibody arrays, and cytokine Luminex panels to validate targets and assess immune modulation. In addition, we offer recombinant protein production in bacterial and mammalian systems, with quality control through SEC, HPLC, mass spectrometry, and endotoxin testing. Our Imaging Services support functional and anatomical analyses using PET, SPECT, CT, and live-cell imaging systems such as Cytation 5. These platforms allow visualization of drug activity, biodistribution, tumor–immune interactions, and therapeutic responses in real time. Ultrastructural characterization using electron microscopy and specialized in vivo functional assays for gastrointestinal absorption and barrier integrity further strengthen our imaging-based assessments. Our Preclinical Models include a wide spectrum of orthotopic, metastatic, and genetically engineered mouse models for breast, lung, pancreatic, prostate, melanoma, and osteosarcoma research. These are complemented by organoid and enteroid systems for both normal tissue and tumor biology, enabling high-throughput efficacy and toxicity screening. Our Bioinformatics Solutions provide advanced analysis of single-cell sequencing, CITE-seq, spatial transcriptomics, bulk RNA-seq, and proteomics datasets. Supported by high-performance computing, our team delivers actionable insights through integrative analyses, pathway discovery, and data visualization. Together, these services create a full-service CRO platform that enables comprehensive evaluation of novel agents—from molecular design and target validation to in vivo efficacy, toxicity, and mechanistic studies—ensuring rigorous and translationally relevant outcomes for our partners.